NCT01445600

ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)

An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ALTARGO(Retapamulin) Administered in Korean Patients According to the Prescribing Information

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,612 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 9 Months
• Healthy volunteers: Not accepted

Summary

This is an open label, multi-centre, non-interventional post-marketing surveillance.

Detailed description

This is an open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of ALTARGO(retapamulin) treated in Korean patients according to the prescribing information. ALTARGO is a trademark of the GlaxoSmithKline group of companies.

Conditions

• Skin Infections, Bacterial

Interventions

Type	Name	Description
DRUG	ALTARGO(retapamulin)	Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Timeline

• Start date: 2012-11-01
• Primary completion: 2015-08-01
• Completion: 2015-08-01
• First posted: 2011-10-04
• Last updated: 2015-09-23

Locations

1 site across 1 country: South Korea